Blue Venture Fund will exit the cancer diagnostics technology startup in a purchase by another of its investors, Exact Sciences, that could reach $2.15bn.
Molecular diagnostics system provider Exact Sciences agreed yesterday to buy one of its portfolio companies US-based cancer screening technology developer Thrive Earlier Detection, for up to $2.15bn in cash and stock.
Exact Sciences will make a $1.7bn upfront payment made up of 65% of stock and 35% of cash while the remaining $450m will be subject to milestones. The deal is expected to conclude in the first quarter of 2021.
Founded in May 2019, Thrive is working on a blood…
